CAS 64228-79-1|atracurium
Introduction：Basic information about CAS 64228-79-1|atracurium, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | atracurium | ||
|---|---|---|---|
| CAS Number | 64228-79-1 | Molecular Weight | 929.144 |
| Density | / | Boiling Point | / |
| Molecular Formula | C53H72N2O12++ | Melting Point | 185-194ºC |
| MSDS | / | Flash Point | / |
Names
| Name | atracurium |
|---|---|
| Synonym | More Synonyms |
atracurium BiologicalActivity
| Description | tracurium (BW-33A free acid) is a potent, competitive and non-depolarizing neuromuscular blocking agent.Atracurium also is an AChR receptor antagonist. Atracurium induces bronchoconstriction and neuromuscular blockade. Atracurium promotes astroglial differentiation[1][2][3][4][5]. |
|---|---|
| Related Catalog | Research Areas >>Cardiovascular DiseaseSignaling Pathways >>Membrane Transporter/Ion Channel >>nAChRSignaling Pathways >>Neuronal Signaling >>nAChRResearch Areas >>Inflammation/Immunology |
| In Vitro | Atracurium (10 µM; 72 h) promotes astroglial but not neuronal differentiation in HSR040622 and HSR040821 cells[4]. Atracurium (10 µM; 48 h) reduces tumor engraftment and increases survival of mice xenotransplanted with ex-vivo treated GSCs[4]. Atracurium (2.4 µM; 120 min) induces a complete fade of the tetanic contraction while only slightly affected the twitch in rat extensor digitorum longus muscle cells[5]. Cell Proliferation Assay[4] Cell Line: glioblastoma stem (GSC) cells Concentration: 3, 10, 20 µM Incubation Time: 72 h Result: Increased the percentage of GFP-positive cells in a dose-dependent manner from 5.3% in DMSO to 15.4%, 81.1%, and 86.8% in 3 μM, 10 μM, and 20 μM, respectively. |
| In Vivo | Atracurium (1, 5, 10, 20, 50 mg/kg; i.v.) induces bronchoconstriction in DBA/2 and SJL mice[2]. Atracurium (4.8 mg/kg; i.v.) induces neuromuscular blockade in rats[3]. Animal Model: 5-12 weeks, 15-20 g male mice[2] Dosage: 1, 5, 10, 20, 50 mg/kg Administration: I.v. Result: Induced bronchoconstriction and Atracurium-induced airway hyperresponsiveness in DBA/2 mice was eliminated in a dose-dependent manner by pretreatment with atropine or pancuronium. Animal Model: 290 ± 30 g Male Sprague±Dawley rats (60 mg/kg heat-killed Corynebacteriumparvum for i.v.)[3] Dosage: 4.8 mg/kg Administration: I.v. Result: Induced neuromuscular blockade in Corynebacteriumparvum-injected rats. |
| References | [1]. Basta SJ, et al. Clinical pharmacology of atracurium besylate (BW 33A): a new non-depolarizing muscle relaxant. Anesth Analg. 1982 Sep;61(9):723-9. [2]. Levitt RC, et al. Genetic susceptibility to atracurium-induced bronchoconstriction. Am J Respir Crit Care Med. 1995 May;151(5):1537-42. [3]. Mayer B, et al. Inflammatory liver disease shortens atracurium-induced neuromuscular blockade in rats. Eur J Anaesthesiol. 2001 Sep;18(9):599-604. [4]. Spina R, et al. Atracurium Besylate and other neuromuscular blocking agents promote astroglial differentiation and deplete glioblastoma stem cells. Oncotarget. 2016 Jan 5;7(1):459-72. [5]. Nascimento DC, et al. Cellular mechanisms of atracurium-induced tetanic fade in the isolated rat muscle. Basic Clin Pharmacol Toxicol. 2004 Jul;95(1):9-14. |
Chemical & Physical Properties
| Melting Point | 185-194ºC |
|---|---|
| Molecular Formula | C53H72N2O12++ |
| Molecular Weight | 929.144 |
| Exact Mass | 928.507446 |
| PSA | 126.44000 |
| LogP | 1.04 |
| InChIKey | YXSLJKQTIDHPOT-UHFFFAOYSA-N |
| SMILES | COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Parenteral
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 520 ug/kg
- TOXIC EFFECTS :
- Cardiac - pulse rate
- REFERENCE :
- BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 287,247,1983
Synonyms
| 5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate |
| 2,2'-{1,5-Pentanediylbis[oxy(3-oxo-3,1-propanediyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium] |
| Isoquinolinium, 2,2'-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl- |
| Atracurium |
| 2,2'-{Pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium] |
| UNII-2GQ1IRY63P |
| Atracurium Dibesylate |
